Comparative Pharmacology
Head-to-head clinical analysis: HALOTESTIN versus ORETON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALOTESTIN versus ORETON.
HALOTESTIN vs ORETON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Androgen receptor agonist; binds to androgen receptors, stimulating protein synthesis, growth of male reproductive tissues, and development of secondary sexual characteristics.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
Testosterone enanthate 50-400 mg IM every 2-4 weeks.
None Documented
None Documented
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
8 hours for testosterone; clinical context: requires daily or weekly dosing for replacement therapy
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Renal (90% as metabolites, 5% unchanged), biliary/fecal (10%)
Category C
Category C
Androgen
Androgen